Daily Newsletter

20 October 2023

Daily Newsletter

20 October 2023

Major work starts on redevelopment of RPA Hospital in Sydney

When complete, the redevelopment will deliver a new 15-storey clinical services building and enhanced emergency units.

October 20 2023

Major construction for the overhaul of the Royal Prince Alfred Hospital (RPA) in Sydney, Australia, has commenced with a sod-turning event.

This comes after the clearance of the State Significant Development Application for the redevelopment work.

Australia's New South Wales (NSW) Government has pledged A$940m ($596m) towards the project, which will be used to deliver a new hospital building and the refurbishment of existing spaces.

This investment is claimed to be the most significant in RPA’s 140-year history.

The sod-turning ceremony for the project saw the presence of NSW Health Minister Ryan Park, Minister for Planning and Public Spaces Paul Scully, and Premier Chris Minns.

Scully noted: “It is an investment in our future to ensure the growing populations have access to the highest quality healthcare for years to come.

“The project will generate 1400 construction jobs and 900 additional health-related jobs when it’s complete.

“I am pleased it will not only be able to provide high-quality healthcare but it will also be able to give the local economy a boost in the process.”

When complete, the project will deliver a new 15-storey clinical services building, as well as expanded and upgraded emergency and intensive care units.

While treatment spaces at the emergency unit will increase from 42 to 91, the adult intensive care bed count will increase from 49 to 74.

The redevelopment will also provide enhanced adult and paediatric inpatient beds, along with operating theatres and more interventional and imaging services.

In addition, the capacity of the hospital’s neonatal intensive care unit and special care nursery will increase to 45 beds, from the existing 34.

A new open garden courtyard, along with improved signage and landscaping, will also be in place across the hospital campus.

AI will become a key driver of medical device innovation

With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close